Literature DB >> 17498392

Dose-dependent pharmacokinetics of telithromycin after intravenous and oral administration to rats: contribution of intestinal first-pass effect to low bioavailability.

Joo Hyun Lee1, Myung Gull Lee.   

Abstract

PURPOSE: To evaluate the pharmacokinetics of telithromycin after intravenous and oral administration and to find the reason for incomplete F value (first pass-effect) after intravenous, intraportal, intragastric, and intraduodenal administration to rats.
METHODS: Telithromycin was administered intravenously or orally at doses of 20, 50, and 100 mg/kg to rats. And hepatic, gastric, and intestinal first-pass effects of telithromycin were also measured after intravenous, intraportal, intragastric, and intraduodenal administration at a dose of 50 mg/kg to rats.
RESULTS: The dose-normalized AUC values of telithromycin were dose-dependent (increased with increasing doses) after both intravenous and oral dose ranges studied, possibly due to saturable metabolism of telithromycin. After oral administration (50 mg/kg), approximately 4.06% of oral dose was not absorbed, F was approximately 27.5%, and the intestinal first-pass effect was approximately 63.4% of oral dose. The first-pass effects of telithromycin in the lung, heart, stomach, and liver were almost negligible, if any, in rats.
CONCLUSIONS: The low F of telithromycin at a dose of 50 mg/kg was mainly due to considerable intestinal first-pass effect, approximately 63.4% of oral dose, in rats.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17498392

Source DB:  PubMed          Journal:  J Pharm Pharm Sci        ISSN: 1482-1826            Impact factor:   2.327


  4 in total

1.  Effects of Escherichia coli lipopolysaccharide on telithromycin pharmacokinetics in rats: inhibition of metabolism via CYP3A.

Authors:  Joo H Lee; Yu K Cho; Young S Jung; Young C Kim; Myung G Lee
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

2.  Pharmacokinetic/Pharmacodynamic Evaluation of Solithromycin against Streptococcus pneumoniae Using Data from a Neutropenic Murine Lung Infection Model.

Authors:  Olanrewaju O Okusanya; Alan Forrest; Sujata M Bhavnani; Prabhavathi Fernandes; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Investigating the barriers to bioavailability of macrolide antibiotics in the rat.

Authors:  Jasna Padovan; Jovica Ralić; Vatroslav Letfus; Astrid Milić; Vlatka Bencetić Mihaljević
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2011-11-24       Impact factor: 2.441

4.  Telithromycin pharmacokinetics in rat model of diabetes mellitus induced by alloxan or streptozotocin.

Authors:  Joo H Lee; Myung G Lee
Journal:  Pharm Res       Date:  2008-05-14       Impact factor: 4.200

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.